JP2019500876A5 - - Google Patents

Download PDF

Info

Publication number
JP2019500876A5
JP2019500876A5 JP2018535126A JP2018535126A JP2019500876A5 JP 2019500876 A5 JP2019500876 A5 JP 2019500876A5 JP 2018535126 A JP2018535126 A JP 2018535126A JP 2018535126 A JP2018535126 A JP 2018535126A JP 2019500876 A5 JP2019500876 A5 JP 2019500876A5
Authority
JP
Japan
Prior art keywords
culture
glycan
monoclonal antibody
man
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018535126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500876A (ja
JP6674028B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/012349 external-priority patent/WO2017120347A1/en
Publication of JP2019500876A publication Critical patent/JP2019500876A/ja
Publication of JP2019500876A5 publication Critical patent/JP2019500876A5/ja
Application granted granted Critical
Publication of JP6674028B2 publication Critical patent/JP6674028B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018535126A 2016-01-06 2017-01-05 モノクローナル抗体組成物中のアフコシル化種の調節 Active JP6674028B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662275384P 2016-01-06 2016-01-06
US62/275,384 2016-01-06
PCT/US2017/012349 WO2017120347A1 (en) 2016-01-06 2017-01-05 Modulation of afucosylated species in a monoclonal antibody composition

Publications (3)

Publication Number Publication Date
JP2019500876A JP2019500876A (ja) 2019-01-17
JP2019500876A5 true JP2019500876A5 (https=) 2020-02-13
JP6674028B2 JP6674028B2 (ja) 2020-04-01

Family

ID=57944513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018535126A Active JP6674028B2 (ja) 2016-01-06 2017-01-05 モノクローナル抗体組成物中のアフコシル化種の調節

Country Status (8)

Country Link
US (1) US20190161543A1 (https=)
EP (1) EP3400241B1 (https=)
JP (1) JP6674028B2 (https=)
CN (1) CN109153716A (https=)
AU (1) AU2017206006B2 (https=)
CA (1) CA3010598A1 (https=)
MX (1) MX2018008447A (https=)
WO (1) WO2017120347A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3057616B1 (en) 2013-10-16 2020-03-11 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
US12325737B2 (en) * 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
HU231514B1 (hu) * 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
AU2019402923A1 (en) * 2018-12-19 2021-07-15 Seagen Inc. Controlled fucosylation of antibodies
WO2021066772A1 (en) * 2019-10-01 2021-04-08 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Cell culture medium for reducing fucosylation and basic variants in the production of antibodies
CN116964215A (zh) * 2021-02-12 2023-10-27 隆萨本德股份有限公司 用于调节抗体产物的无岩藻糖基化的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US8227241B2 (en) 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
CA2608579C (en) 2005-05-26 2019-09-10 Cytos Biotechnology Ag Scalable fermentation process
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2009135181A2 (en) * 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US8409838B2 (en) 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
CA2763164A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
WO2013114165A1 (en) * 2012-01-30 2013-08-08 Dr Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased afucosylation content
NO2760138T3 (https=) * 2012-10-01 2018-08-04
WO2015140700A1 (en) * 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Cell culture process
ES2875274T3 (es) * 2015-11-02 2021-11-10 Hoffmann La Roche Procedimientos de preparación de formas fucosiladas y afucosiladas de una proteína

Similar Documents

Publication Publication Date Title
JP2019500876A5 (https=)
Li et al. Serum-free medium for recombinant protein expression in Chinese hamster ovary cells
Carrillo-Cocom et al. Amino acid consumption in naïve and recombinant CHO cell cultures: producers of a monoclonal antibody
RU2642285C1 (ru) Способ получения целевого антитела с модулированным галактозилированием (варианты) и способ модулирования галактозилирования целевого антитела (варианты) путем оптимизации культуральной среды
BRPI0514680A (pt) produção de anticorpos anti-amilóide beta
Masterton et al. The impact of process temperature on mammalian cell lines and the implications for the production of recombinant proteins in CHO cells
RU2008152449A (ru) Получение гликопротеинов
IL201395A (en) Multi-clonal cell lines and methods for generating multi-clonal cell lines
RU2013152982A (ru) Способ снижения гетерогенности антител и способ получения соответствующих антител
NZ701825A (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
JP2016513478A5 (https=)
MX2018008447A (es) Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal.
JP2016523910A5 (https=)
IL313983A (en) Fully fucose-free glycoforms of antibodies are produced in cell culture
MX2018008448A (es) Reducción de especies de alto peso molecular, especies con carga ácida, y fragmentos en una composición de anticuerpo monoclonal.
CN104560882A (zh) 一种降低酸性变体含量的cho细胞培养工艺
Amribt et al. Optimization and robustness analysis of hybridoma cell fed-batch cultures using the overflow metabolism model
GB0321100D0 (en) Biological products
IL307155B1 (en) Antibodies with modulated glycan profiles
Yoon et al. Biphasic culture strategy for enhancing volumetric erythropoietin productivity of Chinese hamster ovary cells
Lee et al. Effect of hypoosmotic pressure on cell growth and antibody production in recombinant Chinese hamster ovary cell culture
Shi et al. Controlled growth of Chinese hamster ovary cells and high expression of antibody-IL-2 fusion proteins by temperature manipulation
Mahboudi et al. The role of different supplements in expression level of monoclonal antibody against human CD20
CN102604884B (zh) 细胞的发酵培养方法
CN101205530B (zh) 采用动物细胞流加培养方式高效表达重组蛋白的方法